We clarified the clinical prevalence of ovarian metastases from colorectal cancers (CRCs) in 296 female patients with CRC and evaluated clinical outcomes with relation to their mutational profiles, such as BRAF/KRAS mutation and microsatellite instability (MSI) status. The female CRCs were categorised into three subsets: CRCs with ovarian metastases [6.4% (n = 19), 5-year overall survival (OS) = 24.7%], CRCs with extra-ovarian metastases only [32.4% (n = 96), 5-year OS = 34.5%] and CRCs without any recurrence or metastasis [61.2% (n = 181), 5-year OS = 91.3%]. All patients with ovarian metastases underwent oophorectomy; of these, 9 who received preoperative chemotherapy had measurable metastases to extra-ovarian sites and the ovaries. Although 5 of 9 (56%) achieved partial response or complete response at extra-ovarian sites, no patient archived objective response at ovarian sites. Regarding the mutation profiles, in CRCs with extra-ovarian metastases only, the median survival time (MST) after initial treatments to progression to stage IV or recurrence was 13 [95% confidence interval (CI): 7–16 months] in BRAF-mutant and 34 months (95% CI: 22–58 months) in BRAF wild-type (P = 0.0033). Although ovarian metastases demonstrated poor response to systemic chemotherapy in CRCs with ovarian metastases, the MST after initial treatments to progression to stage IV or recurrence was 22 (95% CI: 21–25 months) in BRAF-mutant and 38 months (95% CI: 24–42 months) in BRAF wild-type (P = 0.0398). The outcomes of patients with ovarian metastases could be improved by oophorectomy regardless of their mutation profiles.
For several years, adoptive immunotherapy (AIT) has been performed using autologous zoledronate-activated killer (ZAK) cells to develop a novel modality for cancer treatment. In the current study, data from 50 patients with incurable gastric cancer were analyzed. Patients were treated with AIT using intravenous ZAK cells every 3-4 weeks in combination with chemotherapy of the physician’s choice. The possible clinical benefits were subsequently examined. The median overall survival (OS) time of all patients was 7.5 months. In patients that received 5 or more rounds of treatment, the OS was 13.5 months. Additionally, the OS times of 1st, 2nd or later line chemotherapy with ZAK cell AIT were 27.3 months and 13.3 months, respectively. No objective response was observed and the disease control rate was 67.9%. No severe adverse event was recorded. Functional Assessment of Cancer Therapy-Biologic Response Modifier analysis revealed possible improvement of quality of life after ZAK cell AIT. Univariate analysis revealed a significant positive association between longer survival times and baseline lymphocyte percentages in white blood cell counts (P<0.001), serum albumin (P=0.001), C-reactive protein (P=0.006), carbohydrate antigen (CA)19-9 (P=0.010), neutrophil-lymphocyte ratio (P<0.001) and Glasgow prognostic score (GPS). Only the GPS value (P=0.024) was a significant survival marker when analyzed using the multivariate Cox proportional hazards model. Although the results cannot provide a definitive conclusion, the current suggested that ZAK cell AIT in combination with chemotherapy is safe, feasible and may be a promising treatment option for patients with incurable gastric cancer. The GPS value at baseline may be a potential biomarker for chemo-immunotherapy.
Background/Aim: Adoptive immunotherapy (AIT) using autologous zoledronate-activated killer (ZAK) cells has been performed for developing a novel modality of cancer treatment. In this study, data series from incurable pancreatic cancer were analyzed. Patients and Methods: Patients were treated with AIT using intravenous administration of ZAK cells every 3 to 4 weeks in combination with standard chemotherapy and possible clinical benefits were examined. Results: Seventy-five patients were treated. A median overall survival (OS) time of 6.7 months was achieved for all patients and 13.1 months for those treated 5 times or more, that increased to 14.6 and 18.3 months, respectively, when the previous treatment period of chemotherapy alone was included in the analysis. The disease control rate was 58.5 %. Multivariate regression analysis showed a significant positive correlation between the survival and baseline value of lymphocyte percentage in white blood cell counts (p=0.031). Conclusion: The data suggest that AIT using
Background: The appearance of new lesions and increment in size of target lesions are both considered progressive disease in RECIST 1.1. There had been some previous studies that showed the progression with new lesions rather than without new lesions had more negative impact on overall survival in breast cancer and advanced gastric cancer. We aimed to investigate the such prognostic impact of progression type by RECIST in pancreatic cancer. Methods: We reviewed a retrospective data of total 228 histologically confirmed metastatic pancreatic adenocarcinoma patients treated with 1st line systemic chemotherapy and who showed progressive disease in response evaluation anytime during 1st line gemcitabine based chemotherapy from 2011 to 2017. Progression with appearance of new lesions (PD with NL) and solely size increase of target lesions without new lesion (PD without NL), the two covariates were tested to verify their effects on overall survival (OS), progression free survival (PFS), and post-progression survival (PPS), using a Kaplan-Meier method. Multivariate analysis were done using Cox proportional hazards regression model to examine prognostic factors for PPS and OS. PPS was defined as period between the date of tumour progression observed after 1st-line chemotherapy and the date of death. Results: The OS of PD without NL was 8.8 months (95% CI, 7.056-10.544, p ¼ 0.017), while the OS of PD with NL was 6.4 month (95% CI 5.391-7.475). The PPS of each PD without NL group and PD with NL group were 4.4 months (95% CI, 3.571-5.229) and 2.5 months (95% CI, 1.877 -3.057) with p ¼ 0.001. However, there was no statistical difference between PFS of both groups, which were 3.27 months (95%, 2.452-4.082) and 3.600 (95% CI, 2.937-4.263) with p ¼ 0.410. In multivariate analysis of prognostic factors for overall survival, number of metastatic sites, the 1st line chemotherapy type, and the progression types were statistically significant. Conclusions: By categorizing progressive disease according to the presence of new lesion and analysing the data, the progression with new lesions rather than without new lesions was more negatively associated patient's OS and PPS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.